Urologic Design Secures $1.2M Pre-Seed Funding for New Incontinence Device

Urologic Design, an up-and-coming entity committed to revolutionizing urology care, has announced a successful closing of a pre-seed funding round, where they raised an impressive $1.2 million. This funding marks a significant milestone for the company as they work towards the development of a groundbreaking medical device designed specifically to manage urinary incontinence.

Who Are They?

Founded in 2022 by Dr. David Hesse, an Associate Professor of Urology at Yale School of Medicine, Urologic Design's mission is to bridge the gap between cumbersome absorbent products and invasive surgical options that individuals currently face in managing urinary problems. Headquartered in Branford, Connecticut, the organization is poised to address the serious needs of the 25 million adults in the United States who experience urinary incontinence, a problem that remains largely under-addressed in terms of quality solutions.

The Importance of the Funding

The funds acquired will not only support the development of their first product—a patented urethral occlusion device for men—but also propel ongoing research and development initiatives, regulatory preparations, and the setup for their first-in-human clinical trail. The pre-seed financing was oversubscribed and led by Angel Investor Forum, with additional contributions from HBS Alumni Angels of Boston, Haven Founders Fund, Connecticut Innovations, and Yale Angels, along with various individual investors.

Matthew Stannard, the Life Sciences Lead at Angel Investor Forum, emphasized that their investments focus on companies that address critical unmet needs through distinct solutions. Urologic Design's thorough approach and innovative thinking captured their attention, making it an ideal candidate for investment. Stannard expressed excitement for their journey to initiate first-in-human testing, a vital step towards bringing their product to market.

Product Development Journey

The company is already ahead in many areas, having developed a functional prototype of their device and secured IP protection. The device has undergone extensive bench testing and is now primed for initial clinical studies involving a select group of men suffering from stress urinary incontinence.

Dr. David Hesse, Co-Founder and Chief Scientific Officer, pointed out the substantial inconvenience and discomfort that current options impose on users. Many existing products do not integrate seamlessly into an individual’s lifestyle, leading to feelings of embarrassment and loss of dignity. Urologic Design aims to rectify this by providing a simple yet effective temporary solution that empowers individuals with control and confidence.

The Vision

The overarching vision of Urologic Design is clear: to enhance the quality of life for men suffering from urinary incontinence through advanced technology. Their aim is not just about creating a product but, rather, about creating lasting positive change for millions who deal with this chronic issue daily.

As Urologic Design gears up for testing and eventual commercialization of their device, all eyes will be on them to see how they navigate the complex landscape of medical device development. Their innovations may soon offer a new lifeline to many individuals, helping them regain their dignity and improve their daily lives.

For more information about Urologic Design and their innovative approaches in urology care, visit their official website at www.urologicdesign.com.